Table 1

Characteristics of the study patients with plasma measurements

VariableCONTROL (n=22)FTD (n=51)*C9orf72 (n=10)GRN (n=5)p Value
Gender M/F—no. (%)9 (41)/13 (59)27 (53)/24 (47)7 (70)/3 (30)1 (20)/4 (80)0.230
Age—year (mean±SD)70.1±9.667.8±8.852.4±9.265.2±6.1<0.001†
Age of onset of the disease—year (mean±SD)NA62.9±9.448.8±8.861.2±4.3<0.001†
Disease duration year—(mean±SD)NA5.0±3.53.7±2.44.00±2.70.490
MMSE– Median (IQR)29 (28.75–30)11 (3–24)26 (22–27.25)15 (9.5–27.25)<0.001†
GDS– Median (IQR)1 (1)5 (4–6)4.5 (3–5)4 (4–5)<0.001†
Plasma pTDP-43 levels (relative units)
 Median0.0520.1201.574‡2.970‡0.002†
 (IQR)(0.000–0.279)(0.020–0.829)(0.329–9.732)(1.014–8.706)
Total TDP-43 levels (relative units)
 Median4.3705.8961.488§0.755§0.008†
 (IQR)(3.190–6.925)(3.588–9.396)(1.012–7.225)(0.454–5.254)
  • Data are expressed as mean±SD, number of patients (per cent) or median (IQR), as appropriate. Plasma pTDP-43 and total TDP-43 levels are expressed as values relative to an internal control sample. Probability values (p) denote differences between control, FTD, C9orf72 and GRN patients groups, except for ‘age of onset of the disease’ and ‘disease duration’ where control group is excluded of the analysis. In these variables, the asymptomatic patient in the C9orf72 was not included. χ2 statistics were used for categorical variables. One-way ANOVA was used to compare continuous variables between groups. MMSE, GDS, pTDP-43 and total TDP-43 were evaluated by non-parametric statistical analysis (Kruskal-Wallis).

  • *Total TDP-43 levels were measured in 50 patients with FTD.

  • †Significant difference (p<0.05).

  • ‡p<0.05 in post hoc comparison between C9orf72 or GRN with control and FTD groups (Mann-Whitney).

  • §p<0.05 in post hoc comparison between GRN and control or FTD groups and C9orf72 and FTD group (Mann-Whitney).

  • ANOVA, analysis of variance; FTD, frontotemporal dementia; GDS, Global Deterioration Scale; MMSE, Mini-Mental State Examination; IQR, interquartile range; NA, not applicable.